Bioimaging Nucleic-Acid Aptamers with Different Specificities in Human Glioblastoma Tissues Highlights Tumoral Heterogeneity.
Fiche publication
Date publication
septembre 2022
Journal
Pharmaceutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CHENARD Marie-Pierre, Dr CHOULIER Laurence, Dr DONTENWILL Monique, Dr ETIENNE-SELLOUM Nelly, Pr LEHMANN Maxime, Dr LHERMITTE Benoît
Tous les auteurs :
Cruz Da Silva E, Foppolo S, Lhermitte B, Ingremeau M, Justiniano H, Klein L, Chenard MP, Vauchelles R, Abdallah B, Lehmann M, Etienne-Selloum N, Dontenwill M, Choulier L
Lien Pubmed
Résumé
Nucleic-acid aptamers are of strong interest for diagnosis and therapy. Compared with antibodies, they are smaller, stable upon variations in temperature, easy to modify, and have higher tissue-penetration abilities. However, they have been little described as detection probes in histology studies of human tissue sections. In this study, we performed fluorescence imaging with two aptamers targeting cell-surface receptors EGFR and integrin α5β1, both involved in the aggressiveness of glioblastoma. The aptamers' cell-binding specificities were confirmed using confocal imaging. The affinities of aptamers for glioblastoma cells expressing these receptors were in the 100-300 nM range. The two aptamers were then used to detect EGFR and integrin α5β1 in human glioblastoma tissues and compared with antibody labeling. Our aptafluorescence assays proved to be able to very easily reveal, in a one-step process, not only inter-tumoral glioblastoma heterogeneity (differences observed at the population level) but also intra-tumoral heterogeneity (differences among cells within individual tumors) when aptamers with different specificities were used simultaneously in multiplexing labeling experiments. The discussion also addresses the strengths and limitations of nucleic-acid aptamers for biomarker detection in histology.
Mots clés
EGFR, cell-surface receptors, detection, glioblastoma, histofluorescence, integrin α5β1, multiplexing, nucleic-acid aptamers
Référence
Pharmaceutics. 2022 09 20;14(10):